Cancer of unknown primary origin primary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cancer of unknown primary origin}} {{CMG}}; {{AE}} ==Overview== There are no established measures for the primary prevention of [disease name]. OR There are no...")
 
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
There are no established measures for the primary prevention of [disease name].
There are no primary preventive measures available for cancer of unknown primary origin.
 
OR
 
There are no available vaccines against [disease name].
 
OR
 
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
 
OR
 
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].


==Primary Prevention==
==Primary Prevention==
There are no established measures for the primary prevention of [disease name].
There are no primary preventive measures available for cancer of unknown primary origin.<ref name="pmid15888766">{{cite journal |vauthors=Briasoulis E, Tolis C, Bergh J, Pavlidis N |title=ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP) |journal=Ann. Oncol. |volume=16 Suppl 1 |issue= |pages=i75–6 |year=2005 |pmid=15888766 |doi=10.1093/annonc/mdi804 |url=}}</ref>
 
OR
 
There are no available vaccines against [disease name].
 
OR
 
Effective measures for the primary prevention of [disease name] include:
*[Measure1]
*[Measure2]
*[Measure3]
 
OR


[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
There is no evidence that follow-up of asymptomatic patients is needed.<ref name="pmid15888766" />
*[Strategy 1]
*[Strategy 2]
*[Strategy 3]


==References==
==References==

Revision as of 19:53, 9 February 2019

Cancer of unknown primary origin Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cancer of Unknown Primary Origin from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cancer of unknown primary origin primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cancer of unknown primary origin primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cancer of unknown primary origin primary prevention

CDC on Cancer of unknown primary origin primary prevention

Cancer of unknown primary origin primary prevention in the news

Blogs on Cancer of unknown primary origin primary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Cancer of unknown primary origin primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no primary preventive measures available for cancer of unknown primary origin.

Primary Prevention

There are no primary preventive measures available for cancer of unknown primary origin.[1]

There is no evidence that follow-up of asymptomatic patients is needed.[1]

References

  1. 1.0 1.1 Briasoulis E, Tolis C, Bergh J, Pavlidis N (2005). "ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)". Ann. Oncol. 16 Suppl 1: i75–6. doi:10.1093/annonc/mdi804. PMID 15888766.

Template:WH Template:WS